| Document Date: 2004-09-14 08:01:31
Open Document File Size: 173,51 KBShare Result on Facebook
City Triangle Park / / Company GlaxoSmithKline / BP / GM / ITT / Biometrics / / Country United States / Denmark / / Event FDA Phase / / IndustryTerm inhaled corticosteroid containing drug products / treatment / treatment for the symptoms / serous otitis media / otitis media / / MedicalCondition epistaxis / nosebleeds / cough bronchitis / upper respiratory infections / serous otitis media / perennial allergic rhinitis / allergic and non-allergic rhinitis / patient’s disease / streptococcal pharyngitis / pulmonary studies / pain / vomiting / Pulmonary / allergic rhinitis / diarrhea / tonsillitis / sinusitis / otitis media / cough / upper and lower respiratory infections / allergic rhinitis disease / wheezing / asthma / sore throats / / Organization FDA / Advisory Committee / / Person Elashoff / Eugene Sullivan / / Position investigator / TEAM LEADER / overnight BPCA Clinical Executive / Consultant / Division of Pulmonary and Allergy Drug Products BPCA Clinical Executive Summary NDA / investigator / and gender / raw BPCA Clinical Executive / Executive / Major / MEDICAL OFFICER / / Product Fluticasone propionate / Cutivate / Flonase / Glucocorticoid Intranasal Aqueous suspension / Allergy Drug / Flonase® Nasal Spray / / ProvinceOrState North Carolina / / Technology pdf / /
SocialTag |
BPCA CLINICAL SUMMARY OF NDA[removed], SE8-028 APPLICATION: APPLICANT: MEDICAL OFFICER: TEAM LEADER: